JS107

· Shanghai Junshi Bioscience Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for JS107, covering 2025-06-06 to 2026-01-22. Get the full timeline:

Most recent: Clinical Trial Update: JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. [Phase 3]

See pricing